

---

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

*For the month of June 2024*

Commission file number: 001-35223

**BioLineRx Ltd.**

(Translation of registrant's name into English)

**2 HaMa'ayan Street  
Modi'in 7177871, Israel**  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F** ☒      **Form 40-F** ☐

---

On June 16, 2024, Biokine Therapeutics Ltd. (“Biokine”), filed a complaint with the District Court of Jerusalem against BioLineRx Ltd. (the “Company”), entitled *Biokine Therapeutics Ltd. v. BioLineRx Ltd., T.A. 31677-06-24*. The complaint alleges breach of contract and a purported failure to make certain payments to Biokine under the Company’s in-licensing agreement with Biokine for motixafortide. The lawsuit seeks compensatory damages in the amount of approximately \$6.5 million and a declaratory judgment in favor of Biokine. The Company intends to vigorously defend itself against such action.

This report on Form 6-K is incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

---

Dated: June 18, 2024

By: /s/ Philip A. Serlin

Philip A. Serlin  
Chief Executive Officer